OUTLOOK THERAPEUTICS INC (OTLK)
🔔 Watch stock
symbol.quality_heading
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
The approval is a genuine milestone and removes the single largest risk — but it removes neither the going-concern notice, nor the $30.2 million of debt maturing from late 2026, nor the ongoing dilution. The bet on the regulator has become a bet on the financing; anyone staying invested should size the position against a capital raise on weak terms. The decision is yours.
symbol.quality_note
At the fourth attempt, on July 24, 2026, the U.S. Food and Drug Administration approved what Outlook Therapeutics has been fighting for since 2022: LYTENAVA, the first bevacizumab developed specifically for the eye in the United States. The stock closed 6.4 percent higher that day — on more than five times its usual volume. We read what the approval actually says, what the label reveals about the trials, and why $7.75 million of cash is a very short blanket for a U.S. launch. A regulator's yes is not an invoice that pays itself.
Read the analysis
Stock Watch
This analysis is as of July 17, 2026. Stock Watch will tell you what's changed at OTLK since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 16 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 0.98 $ — 28% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIOutlook Therapeutics ist ein Ophthalmologie-Biotech ohne KI-Umsatzquelle; beide 10-Ks bestätigen aber ausdrücklich, dass Mitarbeiter generative KI für ihre Arbeit einsetzen und ein Verzicht darauf das Geschäft weniger effizient machen und Wettbewerbsnachteile bringen würde.
View the full file — quotes, sources, reviewed filings
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen generative Künstliche-Intelligenz-Technologien (KI), um ihre Arbeit zu verrichten, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und anderen Datenschutzpflichten.
„If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages."
Wenn wir generative KI nicht nutzen können, könnte das unser Geschäft weniger effizient machen und zu Wettbewerbsnachteilen führen.
„Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter und unser Personal nutzen generative Künstliche-Intelligenz-Technologien (KI), um ihre Arbeit zu verrichten, und die Offenlegung und Nutzung personenbezogener Daten in generativen KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und anderen Datenschutzpflichten.
Filings Reviewed: 10-Q 2026-05-15 · 10-Q 2026-02-17 · 10-Q 2025-08-14 · 10-Q 2025-05-15 · 10-K 2025-12-19 · 10-K 2024-12-27
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 461.2% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.09 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.12 | – | 0 | – | 10,222.40 | -11 | -11 |
| 2025: Q1 | -0.31 | – | 0 | – | – | -17 | -17 |
| 2025: Q2 | -0.14 | -145.40 | 2 | – | -1,339.10 | -12 | -12 |
| 2025: Q3 | -0.09 | -333.60 | 0 | -154.10 | – | -12 | -12 |
| 2025: Q4 | -0.16 | -232.70 | -1 | -810.60 | – | -15 | -15 |
| 2026: Q1 | -0.03 | – | 0 | – | -3,506.30 | -8 | -8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
The FDA approved LYTENAVA on July 24, 2026 — at the fourth attempt and five days ahead of its own goal date. The single largest risk in the stock is settled, and the EU (May 2024) and UK (July 2024) approvals remain in place.
Only wet AMD is approved, dosing is monthly (1.25 mg roughly every 28 days) with no interval extension, and the label documents the missed non-inferiority margin of NORSE EIGHT. The twelve-year exclusivity blocks biosimilars, not repackaged Avastin, which accounts for 66.3 percent of new patient starts per Outlook's own annual report.
Going-concern notice in the quarterly report: $7.75 million of cash (March 31, 2026) against roughly $11.8 million of operating outflow per quarter, plus $30.2 million of debt maturing December 31, 2026 and June 16, 2027 — rank 1 in our "Insolvency Radar" (live query July 27, 2026).
Share count from 53.9 million (September 30, 2025) to 187.0 million (June 22, 2026); authorized shares raised from 260 to 600 million on July 16, 2026, a 1-for-10 to 1-for-50 reverse split authorized, and the resale of 17,258,065 shares registered on July 21, 2026.
The European track record is the warning from inside the house: $1.4 million of revenue in fiscal 2025 and negative net revenue in the first half of fiscal 2026 (−$1.08 million); Germany's benefit assessment of October 16, 2025 found no proven added benefit while assigning the highest first-year drug costs in the comparator set. The U.S. sales organization has yet to be built, with 17 full-time employees and no published price as of July 27, 2026.
Three days before the approval, the compensation committee approved cash bonuses totaling $620,000, payable only upon FDA approval by July 31, 2026 — roughly 8 percent of the cash position of March 31, 2026, in a company carrying a going-concern notice (8-K of July 24, 2026, Item 5.02).
At the fourth attempt, Outlook Therapeutics achieved what had defeated it three times: LYTENAVA has been approved in the United States since July 24, 2026. The binary regulatory risk is settled — and the question shifts to the cash box: $7.75 million as of March 31, 2026, $30.2 million of debt, a share count that more than tripled in nine months, and an authorized share pipe doubled to 600 million shortly before the yes. Not investment advice.
- Cash runway computed with the same formula as our scanner: $7.75 million of cash (March 31, 2026) divided by roughly $11.8 million of average quarterly operating outflow (last four reported quarters). Since April 2026, $4.5 million net and about $5.0 million gross arrived from two placements; per management explicitly not sufficient for twelve months.
- Next checkpoints: the quarterly report on August 13, 2026 (cash line and going-concern paragraph) and the U.S. launch announced for "before year-end", with the first published price.
- The price had largely front-run the approval: from a closing price of $0.27 on May 20, 2026 to $1.405 on July 24, 2026; on approval day itself, 6.4 percent was left after an intraday range of $1.12 to $1.75 on roughly 55.6 million shares traded.
- The most recently visible analyst price targets ($0.50 / $1.61 / $10.00) all predate the approval; the frequently cited average near $5.50 emerges from dispersion, not agreement.
About the Company
Outlook Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung und Vermarktung monoklonaler Antikörper für ophthalmologische Indikationen konzentriert.
| Employees | 17 |
|---|---|
| Headquarters | Iselin, NJ |
| Website | outlooktherapeutics.com |
| IPO Date | 13. May 2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Charles Jahr | President, CEO & Director | 1973 |
| Lawrence A. Kenyon CPA | EVP, CFO, Treasurer, Secretary & Director | 1966 |
| Joel Prieve | Senior Vice President of Licensing and M&A | – |
| Surendra Sharma M.D. | Senior Vice President of Medical Affairs | – |
| Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | – |
| Jedd Comiskey | Senior VP - Head of Europe | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Sukhtian Faisal Ghiath | Director | Buy | 95,398 | 1.05 | 99,996 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.